



Company name: DAIICHI SANKYO COMPANY, LIMITED  
 Representative: Sunao Manabe, Representative Director, President and CEO  
 (Code no.: 4568, Prime Market, Tokyo Stock Exchange)  
 Please address inquiries to Kentaro Asakura,  
 Vice President, Corporate Communications Department  
 Telephone: +81-3-6225-1126  
<https://www.daiichisankyo.com>

## Announcement regarding Revision of the Annual Dividend Forecast for the Year Ending March 31, 2023

Tokyo, Japan (October 31, 2022) – Daiichi Sankyo Company, Limited (hereinafter, Daiichi Sankyo) today announced the decision to revise the annual dividend per share forecast for the year ending March 31, 2023 at the meeting of the Board of Directors held on October 31, 2022.

### Details of the Revision of Annual Dividend Forecast

	Annual dividend per share		
	Second quarter	Fiscal year-end	Total
Previous forecast (announced on April 27, 2022)	Yen	Yen	Yen
		13.50	27.00
Revised forecast		15.00	30.00
Result for the year ended March 31, 2023	15.00		
Result for the year ended March 31, 2022	13.50	13.50	27.00

#### <Reason for the Revision>

In order to achieve sustainable growth in corporate value, one of our core business strategies is to determine profit distribution based on comprehensive consideration of the investment necessary for implementing growth strategies, and profit return to shareholders.

During the current 5-year business plan period (fiscal year 2021 through fiscal year 2025), in addition to maintaining the ordinary dividend of JPY27.00 per share, we will take account of our profit growth and increase dividend. We will also flexibly conduct share buy-back and will enhance shareholder return.

In consideration of above stated strategy and forecast for consolidated financial results for the year ending March 31, 2023 which was revised upwards today, we will revise the interim dividend and the

year-end dividend forecast for the year ending March 31, 2023 from JPY13.50 per share to JPY15.00 per share, respectively.

As a result, the annual dividend for the year ending March 31, 2023 is planned to be JPY30.00 per share, an increase of JPY3.00 from the previous fiscal year.

### **About Daiichi Sankyo**

Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose “to contribute to the enrichment of quality of life around the world.” In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical needs. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an “Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.” For more information, please visit: [www.daiichisankyo.com](http://www.daiichisankyo.com).